Obstructive Lung Disease

Is There an “Ideal” Cystic Fibrosis Candidate for Lung Transplantation?

By

Suzanne Bujara

Publish Date August 23, 2018

Lung transplantation can extend survival in patients with cystic fibrosis who have compromised lung function and increasing exacerbations.

Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis

By

Britt Gambino

Publish Date November 8, 2019

The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.

Long-Term Azithromycin Reduced Need for IV Antibiotics in Cystic Fibrosis

By

Brandon May

Publish Date November 6, 2019

Treatment with azithromycin during a 5-year period was associated with reductions in the use of intravenous antibiotics and pulmonary exacerbations in children with cystic fibrosis.

Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis

Publish Date November 6, 2019

The percentage of FEV1 higher was at 4 weeks and through 24 weeks with treatment vs placebo.

FDA Approves Triple Combination Therapy for Cystic Fibrosis

By

Brian Park, PharmD

Publish Date October 23, 2019

The FDA has approved Trikafta for the treatment of patients aged 12 years and older with cystic fibrosis.

Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes

By

Heidi Moore

Publish Date October 19, 2019

Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.

Lumacaftor-Ivacaftor Improves Lung Function in Cystic Fibrosis After 1 Year

Publish Date October 16, 2019

After one year of therapy, patients had improved lung function, increased BMI, and a reduced need for intravenous antibiotics.

New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis

By

Virginia A. Schad, PharmD, RPh

Publish Date September 27, 2019

A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.

Comparing Efficacy of Once vs Thrice Daily Aminoglycosides in Cystic Fibrosis

By

Brandon May

Publish Date September 24, 2019

Once- and thrice-daily treatment with aminoglycosides appear to be equally effective for reducing pulmonary exacerbations in cystic fibrosis.